Charles Schwab Investment Management Inc. Has $14.89 Million Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Charles Schwab Investment Management Inc. increased its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 4.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,979,992 shares of the biotechnology company’s stock after buying an additional 91,998 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in BioCryst Pharmaceuticals were worth $14,890,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Venturi Wealth Management LLC acquired a new stake in BioCryst Pharmaceuticals during the 4th quarter worth $46,000. R Squared Ltd acquired a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter valued at about $48,000. KBC Group NV raised its stake in shares of BioCryst Pharmaceuticals by 80.1% in the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock valued at $77,000 after purchasing an additional 4,537 shares during the period. Quantinno Capital Management LP acquired a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter valued at about $82,000. Finally, SkyView Investment Advisors LLC raised its stake in shares of BioCryst Pharmaceuticals by 30.0% in the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 3,000 shares during the period. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

NASDAQ:BCRX opened at $7.69 on Friday. The stock’s 50-day simple moving average is $8.12 and its 200 day simple moving average is $7.83. The company has a market cap of $1.61 billion, a P/E ratio of -12.61 and a beta of 1.85. BioCryst Pharmaceuticals, Inc. has a 52-week low of $4.03 and a 52-week high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. The business’s revenue was up 40.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.28 earnings per share. As a group, equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. Evercore ISI lifted their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Royal Bank of Canada reissued an “outperform” rating and issued a $11.00 price target (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. Wedbush assumed coverage on BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They issued an “outperform” rating and a $15.00 price target on the stock. Finally, JMP Securities reissued a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $15.57.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.